KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Liabilities and Shareholders Equity (2016 - 2026)

Pacira BioSciences has reported Liabilities and Shareholders Equity over the past 17 years, most recently at $1.2 billion for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity fell 23.83% year-over-year to $1.2 billion; the TTM value through Mar 2026 reached $5.3 billion, down 15.86%, while the annual FY2025 figure was $1.3 billion, 18.58% down from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 was $1.2 billion at Pacira BioSciences, down from $1.3 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $1.9 billion in Q1 2022 and troughed at $1.2 billion in Q1 2026.
  • A 5-year average of $1.6 billion and a median of $1.6 billion in 2024 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 46.91% in 2022 and later dropped 23.83% in 2026.
  • Year by year, Liabilities and Shareholders Equity stood at $1.7 billion in 2022, then fell by 6.35% to $1.6 billion in 2023, then dropped by 1.33% to $1.6 billion in 2024, then decreased by 18.58% to $1.3 billion in 2025, then dropped by 4.46% to $1.2 billion in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for PCRX at $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.